Stock listing
NASDAQ:QTRX Quanterix Corporation Stock
Home listing (NASDAQ) of Quanterix Corporation
Follow Quanterix Corporation into a list and get an email when it puts out news.
Share price · NASDAQ:QTRX
$1.96 USD -0.07 (-3.4%)
Close on Nov 20, 2026
- Day range
- $1.78 – $2.03 USDNov 20, 2026
- Volume
- 1.06M sharesNov 20, 2026
- Market cap
- $93.06M USDAt the close on Nov 20, 2026 · price × 47.48M shares outstanding
- 52-week range
- $1.77 – $8.77 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $2.01M USDMedian day 506,100 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:QTRX · Home | $1.96 USD | -0.07 (-3.4%) | 1,055,963 | $1.98 | $2.03 | $1.775 | $2.03 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:QTRX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.96 | -0.07 | -3.4% | $1.98 | $2.03 | $1.775 | 1,055,963 | |
| $2.03 | -0.04 | -1.9% | $2.07 | $2.08 | $1.765 | 2,129,295 | |
| $2.07 | -0.79 | -27.6% | $2.43 | $2.59 | $2.045 | 3,539,869 | |
| $2.86 | +0.02 | +0.7% | $2.84 | $2.97 | $2.82 | 499,644 | |
| $2.84 | -0.09 | -3.1% | $2.90 | $2.92 | $2.715 | 618,247 | |
| $2.93 | +0.07 | +2.4% | $2.90 | $3.035 | $2.78 | 394,300 | |
| $2.86 | -0.16 | -5.3% | $2.98 | $3.10 | $2.855 | 619,300 | |
| $3.02 | -0.26 | -7.9% | $3.33 | $3.40 | $2.985 | 507,100 | |
| $3.28 | -0.10 | -3.0% | $3.42 | $3.53 | $3.18 | 740,700 | |
| $3.38 | +0.485 | +16.8% | $2.91 | $3.44 | $2.827 | 1,175,600 | |
| $2.895 | +0.135 | +4.9% | $2.81 | $2.93 | $2.78 | 474,800 | |
| $2.76 | -0.28 | -9.2% | $3.01 | $3.01 | $2.715 | 357,300 | |
| $3.04 | +0.10 | +3.4% | $2.99 | $3.13 | $2.925 | 402,200 | |
| $2.94 | +0.13 | +4.6% | $2.87 | $2.98 | $2.87 | 266,900 | |
| $2.81 | -0.095 | -3.3% | $2.94 | $2.94 | $2.735 | 510,500 | |
| $2.905 | -0.24 | -7.6% | $3.10 | $3.105 | $2.83 | 361,300 | |
| $3.145 | +0.025 | +0.8% | $3.11 | $3.21 | $3.095 | 334,200 | |
| $3.12 | +0.23 | +8.0% | $2.87 | $3.12 | $2.84 | 658,100 | |
| $2.89 | +0.06 | +2.1% | $2.86 | $2.96 | $2.82 | 467,700 | |
| $2.83 | -0.03 | -1.0% | $2.86 | $2.896 | $2.79 | 257,100 | |
| $2.86 | +0.02 | +0.7% | $2.82 | $2.88 | $2.71 | 349,800 | |
| $2.84 | +0.05 | +1.8% | $2.74 | $2.895 | $2.71 | 496,300 | |
| $2.79 | +0.07 | +2.6% | $2.71 | $2.815 | $2.675 | 525,200 | |
| $2.72 | -0.05 | -1.8% | $2.77 | $2.845 | $2.71 | 536,400 | |
| $2.77 | -0.10 | -3.5% | $2.87 | $2.93 | $2.72 | 430,100 | |
| $2.87 | -0.20 | -6.5% | $3.07 | $3.07 | $2.835 | 322,600 | |
| $3.07 | +0.01 | +0.3% | $3.05 | $3.105 | $2.92 | 291,100 | |
| $3.06 | -0.09 | -2.9% | $3.10 | $3.23 | $3.05 | 342,300 | |
| $3.15 | -0.01 | -0.3% | $3.17 | $3.335 | $3.11 | 749,900 | |
| $3.16 | -0.12 | -3.7% | $3.28 | $3.35 | $3.07 | 562,800 | |
| $3.28 | +0.07 | +2.2% | $3.22 | $3.445 | $3.20 | 282,600 | |
| $3.21 | -0.115 | -3.5% | $3.25 | $3.25 | $3.061 | 606,100 | |
| $3.325 | -0.115 | -3.3% | $3.40 | $3.55 | $3.31 | 493,500 | |
| $3.44 | -0.37 | -9.7% | $3.83 | $3.98 | $3.42 | 606,400 | |
| $3.81 | +0.17 | +4.7% | $3.66 | $3.897 | $3.62 | 1,032,200 | |
| $3.64 | +0.23 | +6.7% | $3.44 | $3.69 | $3.44 | 590,800 | |
| $3.41 | -0.30 | -8.1% | $3.72 | $3.72 | $3.375 | 629,200 | |
| $3.71 | +0.04 | +1.1% | $3.67 | $3.72 | $3.59 | 545,300 | |
| $3.67 | +0.15 | +4.3% | $3.52 | $3.71 | $3.454 | 623,400 | |
| $3.52 | +0.25 | +7.6% | $3.25 | $3.674 | $3.23 | 1,044,600 | |
| $3.27 | +0.09 | +2.8% | $3.23 | $3.29 | $3.105 | 563,500 | |
| $3.18 | +0.02 | +0.6% | $3.15 | $3.22 | $3.041 | 374,200 | |
| $3.16 | -0.03 | -0.9% | $3.17 | $3.198 | $3.03 | 423,700 | |
| $3.19 | +0.15 | +4.9% | $3.05 | $3.21 | $3.03 | 424,900 | |
| $3.04 | -0.03 | -1.0% | $3.13 | $3.175 | $3.005 | 627,400 | |
| $3.07 | -0.05 | -1.6% | $3.12 | $3.14 | $3.00 | 1,048,100 | |
| $3.12 | +0.21 | +7.2% | $2.94 | $3.19 | $2.90 | 955,700 | |
| $2.91 | +0.19 | +7.0% | $2.72 | $2.955 | $2.66 | 924,900 | |
| $2.72 | +0.22 | +8.8% | $2.50 | $2.79 | $2.495 | 1,595,200 | |
| $2.50 | -0.06 | -2.3% | $2.50 | $2.685 | $2.37 | 6,093,200 | |
| $2.56 | +0.06 | +2.4% | $2.52 | $2.59 | $2.50 | 323,000 | |
| $2.50 | -0.15 | -5.7% | $2.60 | $2.625 | $2.49 | 456,100 | |
| $2.65 | -0.08 | -2.9% | $2.70 | $2.715 | $2.61 | 266,200 | |
| $2.73 | +0.04 | +1.5% | $2.64 | $2.83 | $2.61 | 647,400 | |
| $2.69 | +0.11 | +4.3% | $2.58 | $2.695 | $2.54 | 274,600 | |
| $2.58 | -0.03 | -1.1% | $2.63 | $2.64 | $2.43 | 842,000 | |
| $2.61 | +0.10 | +4.0% | $2.49 | $2.64 | $2.49 | 459,000 | |
| $2.51 | -0.16 | -6.0% | $2.59 | $2.62 | $2.50 | 904,100 | |
| $2.67 | +0.03 | +1.1% | $2.62 | $2.675 | $2.53 | 401,300 | |
| $2.64 | 0.00 | 0.0% | $2.64 | $2.67 | $2.58 | 349,500 | |
| $2.64 | -0.04 | -1.5% | $2.66 | $2.736 | $2.62 | 413,000 | |
| $2.68 | -0.11 | -3.9% | $2.83 | $2.86 | $2.65 | 381,800 | |
| $2.79 | -0.01 | -0.4% | $2.80 | $2.96 | $2.775 | 505,100 | |
| $2.80 | -0.19 | -6.4% | $2.99 | $3.00 | $2.752 | 499,000 | |
| $2.99 | -0.13 | -4.2% | $3.11 | $3.11 | $2.99 | 321,200 | |
| $3.12 | +0.16 | +5.4% | $2.96 | $3.25 | $2.86 | 579,100 |
- Ticker
- NASDAQ:QTRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Quanterix Announces Leadership Transition Plan
Latest earnings call · Nov 9, 2026
Quanterix (NASDAQ:QTRX) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 9, 2026
Q3 2026 Earnings Presentation
Earnings · 21 slides
Latest news
Quanterix Announces Leadership Transition Plan
Nov 18, 2026
Closed $2.07 (-27.6%) on Nov 18, 2026
Quanterix Expands Access to Blood-Based Alzheimer's Testing in New Jersey and Surrounding Area Through Exclusive Partnership with Sherman Abrams Laboratory
Nov 16, 2026
Closed $2.84 (-3.1%) on Nov 16, 2026
Quanterix Releases Financial Results for the Third Quarter of 2026
Nov 9, 2026
Closed $3.38 (+16.8%) on Nov 9, 2026
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
Oct 28, 2026
Closed $3.15 (+0.8%) on Oct 29, 2026
Quanterix and Innovita Expand IVD Access in China with National Medical Products Administration Approvals
Oct 7, 2026
Closed $3.33 (-3.3%) on Oct 7, 2026
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Sep 25, 2026
Closed $3.27 (+2.8%) on Sep 25, 2026
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Sep 14, 2026
Closed $2.50 (-2.3%) on Sep 14, 2026
Quanterix Names Jim Gute Chief Commercial Officer
Aug 10, 2026
Closed $2.42 (-40.0%) on Aug 10, 2026
Quanterix Releases Financial Results for the Second Quarter of 2026
Aug 10, 2026
Closed $2.42 (-40.0%) on Aug 10, 2026
Quanterix To Participate in Canaccord Genuity Capital Markets 46th Annual Growth Conference on August 11-12
Aug 6, 2026
Closed $3.83 (+1.9%) on Aug 6, 2026
Quanterix Corporation on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 33 in the last 12 months · 122 in all · newest Nov 18, 2026 · oldest 2019
- Calls
- 22 calls with a replay · 22 with a transcript · latest Nov 9, 2026
- Decks
- 47 decks · latest Nov 9, 2026
Where Quanterix Corporation is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:QTRX · Home listing · This page | NASDAQ | United States | USD |
| BOATS:QTRX | BOATS | United States | USD |
Valuation
EV/sales 0.3× against a median of 3.0×: the lowest of 11 Diagnostics & research services companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $47.06M USD
- P/E
- Loss
- EV/sales
- 0.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.4×
- Gross margin
- 44.5%
- Operating margin
- −93.2%
- Net margin
- −75.0%
- Debt to equity
- 0.1×
- Beta vs S&P 500
- 1.87
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Quanterix Corporation · NASDAQ:QTRX | US$93.06M | US$47.06M | n/a | 0.3× | n/a | 0.4× | −75.0% | 0.1× | 1.87 |
| Photocure ASA · OSL:PHO | US$113.9M | US$97.23M | 22.9× | 1.4× | 6.1× | 1.9× | 7.1% | 0.0× | n/a |
| ArcticZymes Technologies ASA · OSL:AZT | US$108.4M | US$80.84M | 66.1× | 6.2× | 24.6× | 3.0× | 12.7% | 0.0× | n/a |
| NanoenTek, Inc. · KRX:039860 | US$107.8M | US$71.26M | 24.8× | 2.2× | 17.4× | 1.5× | 13.3% | 0.0× | n/a |
| BICO Group AB Class B · OMXSTO:BICO | US$102.7M | US$90.50M | n/a | 0.6× | 2.1× | 0.8× | −28.3% | 0.3× | n/a |
| Devyser Diagnostics AB · OMXSTO:DVYSR | US$99.24M | US$94.86M | 39.9× | 3.8× | 17.5× | 2.6× | 10.0% | 0.1× | n/a |
| Exagen Inc. · NASDAQ:XGN | US$92.10M | US$86.82M | n/a | 1.2× | n/a | 6.7× | −25.1% | 1.7× | 2.52 |
| Biodesix, Inc. · NASDAQ:BDSX | US$83.83M | US$105.4M | n/a | 1.0× | n/a | 9.7× | −25.7% | 5.8× | 1.56 |
| Bonraybio Co. Ltd. · TWSE:6955 | US$81.85M | US$65.60M | 25.0× | 6.5× | 18.1× | 4.1× | 32.5% | 0.0× | n/a |
| Nightingale Health Oyj Class B · OMXHEX:HEALTH | US$77.17M | US$36.79M | n/a | 6.1× | n/a | 1.4× | −335.7% | 0.0× | n/a |
| Lucid Diagnostics Inc. · NASDAQ:LUCD | US$77.14M | US$77.63M | n/a | 14.3× | n/a | 13.0× | −892.8% | 3.1× | 1.36 |
| Median of the others | US$95.67M | US$83.83M | 25.0× | 3.0× | 17.5× | 2.8× | −9.0% | 0.1× | 1.56 |
Forecasts
3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 3.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.96 · 3 analysts
- Revenue, year to Dec 2026
- 143.2M · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jim Gute | Chief Commercial Officer and Interim President and CEO |
| Jason Faessler | Chief Financial Officer |
| Ivana Magovčević-Liebisch | President |
| Anthony Catalano | Chief Operating Officer |
| Jeffrey Elliott | COO of Exact Sciences |
| Daniel Char | Chief Legal Officer |
| Joshua Young | Investor Relations |
| Bill Donnelly | Executive Chair of the Board, Director, Retired EVP, Mettler-Toledo International |
| Geoff Albrecht | SVP, General Manager, Diagnostics |
| Erica Bell | Chief People Officer |
| Michael Miller | Chief Technology and Product Officer |
| Naren Bhat | Chief Strategy Officer |
| Yuri Fesko | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Bill Donnelly | Executive Chair of the Board, Director, Retired EVP, Mettler-Toledo International |
Events
Calls
| Call | When | Status |
|---|---|---|
| Quanterix (NASDAQ:QTRX) Q3 2026 Earnings Call | Mon, Nov 09, 2026 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2026 Earnings Call | Mon, Aug 10, 2026 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q1 2026 Earnings Call | Wed, May 06, 2026 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2025 Earnings Call | Mon, Nov 10, 2025 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 4:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q1 2025 Earnings Call | Mon, May 12, 2025 · 5:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q4 2024 Earnings Call | Mon, Mar 17, 2025 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2024 Earnings Call | Tue, Nov 12, 2024 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q1 2024 Earnings Call | Wed, May 08, 2024 · 8:30 AM ET | Replay |
All 22 calls
| Call | When | Status |
|---|---|---|
| Quanterix (NASDAQ:QTRX) Q4 2023 Earnings Call | Thu, Feb 29, 2024 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2023 Earnings Call | Tue, Nov 07, 2023 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2023 Earnings Call | Tue, Aug 08, 2023 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q1 2023 Earnings Call | Tue, May 09, 2023 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q4 2022 Earnings Call | Mon, Mar 06, 2023 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2022 Earnings Call | Tue, Nov 08, 2022 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2022 Earnings Call | Mon, Aug 08, 2022 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q1 2022 Earnings Call | Tue, May 10, 2022 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q4 2021 Earnings Call | Tue, Mar 01, 2022 · 8:30 AM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2021 Earnings Call | Thu, Nov 04, 2021 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q2 2021 Earnings Call | Thu, Aug 05, 2021 · 4:30 PM ET | Replay |
| Quanterix (NASDAQ:QTRX) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 9, 2026 · Before open | +16.8% |
| Q2 2026 | Aug 10, 2026 · Before open | −40.0% |
| Q1 2026 | May 6, 2026 · After close | −16.4% |
| Q4 2025 | Mar 3, 2026 | −7.4% |
| Q3 2025 | Nov 10, 2025 · After close | −2.3% |
| Q2 2025 | Aug 7, 2025 · After close | −13.8% |
| Q1 2025 | May 12, 2025 · After close | −19.0% |
| Q4 2024 | Feb 26, 2025 · Before open | +1.5% |
| Q3 2024 | Dec 26, 2024 · Before open | +5.2% |
| Q2 2024 | Aug 8, 2024 · After close | −14.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −4.9% |
| Q4 2023 | Feb 29, 2024 · After close | +12.7% |
| Q3 2023 | Nov 6, 2023 · After close | +2.2% |
| Q2 2023 | Aug 7, 2023 · After close | +16.9% |
| Q1 2023 | May 9, 2023 · After close | +0.6% |
| Q4 2022 | Mar 6, 2023 · Before open | +12.1% |
| Q3 2022 | Nov 8, 2022 · After close | +1.3% |
| Q2 2022 | Aug 8, 2022 · After close | −54.8% |
| Q1 2022 | May 10, 2022 · After close | −8.3% |
| Q4 2021 | Mar 1, 2022 · Before open | −6.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 21 slides | Nov 9, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 21 slides | Aug 10, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 17 slides | May 6, 2026 |
| FY2025 Earnings Presentation | Earnings | 14 slides | Mar 2, 2026 |
| Q3 2025 Earnings Presentation | Earnings | 11 slides | Nov 10, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 12 slides | Aug 7, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 19 slides | May 12, 2025 |
| Proxy Contest (April 2025) | Proxy contest | 8 slides | Apr 21, 2025 |
| Q4 2024 Earnings Presentation | Earnings | 15 slides | Mar 17, 2025 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 31 slides | Jan 15, 2025 |
All 47 decks
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 138.9M | 137.4M | 122.4M | 105.5M | 110.6M | 86.4M | 56.7M | 37.6M | 22.9M | 17.6M |
| Cost of revenue | 73.9M | 54.3M | 48.1M | 60.2M | 45.8M | 38.2M | 29.9M | 19.7M | 12.9M | 9.84M |
| Gross profit | 65.0M | 83.1M | 74.2M | 45.4M | 64.8M | 48.2M | 26.8M | 17.9M | 9.99M | 7.75M |
| Research and development | 35.9M | 31.1M | 26.1M | 26.8M | 28.4M | 20.2M | 16.2M | 15.8M | 16.3M | 17.0M |
| Selling, general and administrative | 138.0M | 101.6M | 89.1M | 91.9M | 92.9M | 59.6M | 52.2M | 33.7M | 19.7M | 12.5M |
| Operating income | -125.5M | -52.6M | -46.0M | -104.3M | -56.5M | -31.6M | -41.6M | -31.6M | -26.0M | -21.7M |
| Depreciation and amortization | 15.8M | 6.46M | 6.28M | 5.41M | 4.88M | 4.31M | 3.01M | 1.35M | 482.0K | 444.0K |
| EBITDA | -109.7M | -46.2M | -39.7M | -98.9M | -51.6M | -27.3M | -38.6M | -30.2M | -25.5M | -21.3M |
| Interest expense | 15.8M | 5.13M | 403.0K | 273.0K | 627.0K | 46.0K | 952.0K | 1.30M | ||
| Income before tax | -112.3M | -38.1M | -27.6M | -99.4M | -55.6M | -31.9M | -41.0M | -31.5M | -27.0M | -23.2M |
| Income tax | -5.12M | 434.0K | 719.0K | 164.0K | -36.0K | -376.0K | -187.0K | 25.0K | 0 | 1.13M |
| Net income | -107.2M | -38.5M | -28.4M | -99.6M | -55.5M | -31.5M | -40.8M | -31.5M | -27.0M | -23.2M |
| Earnings per share, basic | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 | -1.07 | -1.63 | -1.41 | -1.24 | -0.82 |
| Earnings per share, diluted | -2.51 | -1.00 | -0.75 | -2.69 | -1.54 | -1.07 | -1.63 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 29.8M | 56.7M | 174.4M | 338.7M | 396.5M | 181.6M | 109.2M | 44.4M | 79.7M | 29.7M |
| Short-term investments | 88.4M | 0 | 6.89M | 0 | ||||||
| Receivables | 30.0M | 32.1M | 25.4M | 19.0M | 23.8M | 17.2M | 10.9M | 6.79M | 5.60M | 3.92M |
| Inventory | 54.8M | 32.8M | 26.1M | 17.0M | 22.2M | 14.9M | 10.5M | 5.95M | 3.57M | 1.53M |
| Current assets | 212.3M | 363.6M | 382.1M | 381.5M | 449.0M | 219.6M | 132.7M | 59.5M | 89.3M | 35.2M |
| Property, plant and equipment | 23.7M | 17.1M | 17.9M | 19.8M | 18.0M | 13.9M | 12.0M | 2.92M | 1.87M | 1.22M |
| Goodwill | 26.4M | 0 | 0 | 0 | 9.63M | 10.5M | 9.35M | 1.31M | ||
| Total assets | 418.8M | 406.5M | 428.6M | 433.6M | 501.5M | 271.0M | 170.0M | 67.6M | 91.8M | 37.1M |
| Accounts payable | 13.6M | 6.95M | 5.05M | 3.84M | 9.21M | 6.80M | 5.78M | 5.11M | 3.55M | 2.55M |
| Current liabilities | 74.8M | 42.0M | 39.0M | 31.3M | 37.0M | 39.8M | 19.8M | 18.1M | 19.7M | 11.0M |
| Long-term debt | 7.59M | 7.62M | 4.35M | 9.34M | ||||||
| Total debt | 37.2M | 37.4M | 41.5M | 44.1M | 21.9M | 7.69M | 7.69M | 7.76M | 9.38M | 13.0M |
| Total liabilities | 123.0M | 76.5M | 78.6M | 75.7M | 60.6M | 64.9M | 41.3M | 26.5M | 25.9M | 23.6M |
| Shareholders' equity | 295.7M | 330.0M | 350.0M | 357.9M | 442.8M | 205.8M | 128.7M | 41.1M | 65.9M | -115.1M |
| Shares outstanding | 46.7M | 38.6M | 38.0M | 37.3M | 36.8M | 31.8M | 28.1M | 22.4M | 21.7M | 28.2M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -77.2M | -35.2M | -18.8M | -48.6M | -47.6M | -23.4M | -26.2M | -28.7M | -22.1M | -17.7M |
| Capital spending | -2.61M | -3.37M | -3.84M | -11.6M | -13.7M | -3.93M | -10.8M | -1.52M | -1.13M | -526.0K |
| Free cash flow | -79.8M | -38.5M | -22.7M | -60.2M | -61.3M | -27.3M | -37.0M | -30.2M | -23.2M | -18.3M |
| Cash from investing | 50.2M | -82.3M | -148.5M | -11.1M | -6.40M | -626.0K | -25.4M | -5.45M | -1.13M | -826.0K |
| Cash from financing | -708.0K | 456.0K | 2.69M | 2.31M | 270.8M | 96.2M | 116.2M | -78.0K | 73.2M | 45.9M |
| Share buybacks | -198.0K | 2.31M | 278.5M | 96.3M | 116.2M | -20.0K | 74.2M | 45.7M | ||
| Change in cash | -27.7M | -117.0M | -164.6M | -57.2M | 216.6M | 72.2M | 64.6M | -34.3M | 50.0M | 27.3M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 18, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Nov 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 10, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 9, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Sep 10, 2026 | Offer document | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 14, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 10, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 10, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 9, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 1, 2026 | Insider trade | SEC |
| 8-K · Current report | May 26, 2026 | Management or board change | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 8-K · Current report | May 12, 2026 | Management or board change | SEC |
| DEFA14A · Additional proxy material | May 8, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 1, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 24, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 24, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 7, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Mar 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 17, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 21, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 21, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 15, 2026 | Offer document | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Dec 22, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 8, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 20, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Oct 2, 2025 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Sep 23, 2025 | Meeting notice | SEC |
| 8-K · Current report | Sep 23, 2025 | Meeting outcome | SEC |
| 8-K/A · Current report, amended | Sep 23, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Aug 25, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Aug 25, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Aug 8, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Aug 4, 2025 | Material contract | SEC |
| 4 · Change in ownership | Aug 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 24, 2025 | Current report | SEC |
| 8-K · Current report | Jul 18, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 15, 2025 | Big-stake notice | SEC |
| S-8 POS | Jul 11, 2025 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Jul 11, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 8, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2025 | Insider trade | SEC |
| 424B3 · Prospectus | Jun 13, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Jun 13, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 11, 2025 | Other filings | SEC |
| DFAN14A | Jun 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Jun 3, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Jun 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | Jun 2, 2025 | ESG report | SEC |
| UPLOAD · Letter from the SEC | May 30, 2025 | Other filings | SEC |
| DFAN14A | May 23, 2025 | Other filings | SEC |
| POS AM · Amendment to an effective registration | May 20, 2025 | Offer document | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 14, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 14, 2025 | Current report | SEC |
| 10-Q · Quarterly report | May 12, 2025 | Quarterly report | SEC |
| 425 | May 12, 2025 | Other filings | SEC |
| 8-K · Current report | May 12, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 2, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Apr 30, 2025 | Annual report | SEC |
| DFAN14A | Apr 30, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| 425 | Apr 29, 2025 | Other filings | SEC |
| 8-K · Current report | Apr 29, 2025 | Material contract | SEC |
| DFAN14A | Apr 24, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 23, 2025 | Big-stake notice | SEC |
| DFAN14A | Apr 22, 2025 | Other filings | SEC |
| DFAN14A | Apr 21, 2025 | Other filings | SEC |
| DFAN14A | Apr 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 17, 2025 | Insider trade | SEC |
| DEFC14A | Apr 17, 2025 | Other filings | SEC |
| 424B3 · Prospectus | Apr 15, 2025 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 15, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 11, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 10, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 10, 2025 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 9, 2025 | Other filings | SEC |
| DFAN14A | Apr 7, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Apr 7, 2025 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 4, 2025 | Offer document | SEC |
| 8-K · Current report | Apr 4, 2025 | Material contract | SEC |
| 425 | Apr 4, 2025 | Other filings | SEC |
This page holds 200 of 1,001 filings. Open Filings
Cap table
Built by 6ix from Quanterix Corporation’s releases · as of Nov 2, 2026
- Common shares
- 47,478,422
- Fully diluted
- 47,478,422
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 47,478,422 | Nov 2, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 2, 2026 | 47,478,422 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Paul Meister Other companies: Versigent PLC (Director · Since at least Apr 1, 2026); Amneal Pharmaceuticals, Inc. (Chairman of the Board · Since at least Aug 2, 2019); Aptiv PLC (Lead Independent Director · Since at least Jul 25, 2019); Oaktree Acquisition Corp. III Life Sciences (Director · Oct 23, 2024 – Oct 23, 2024 · Past); Telesis Bio, Inc. (Director · Jun 5, 2023 – Jun 6, 2023 · Past); Oaktree Acquisition II Corp (Director · Sep 16, 2020 – Sep 16, 2020 · Past); Hims & Hers Health, Inc. (Director · Jul 17, 2019 – Jul 17, 2019 · Past); Revlon Inc (Director · Jun 9, 2016 – Jun 9, 2016 · Past); vTv Therapeutics Inc. (Director · Jul 30, 2015 – Jul 30, 2015 · Past); Light & Wonder, Inc. (Director · Mar 20, 2012 – Jun 10, 2020 · Past); M & F Worldwide Corp (Director · Apr 30, 2007 – Dec 21, 2011 · Past); Thermo Fisher Scientific Inc (Director · Nov 9, 2006 – Jan 5, 2007 · Past); LKQ Corporation (Director · Mar 31, 2006 – May 8, 2017 · Past); Fisher Scientific International Inc (Vice Chairman, Director · Jan 13, 2006 – Nov 9, 2006 · Past) | Director · Since at least Dec 6, 2017 |
| Douglas G Cole Other companies: Foghorn Therapeutics Inc. (Director · Since at least Oct 22, 2020); Sana Biotechnology, Inc. (Director · Feb 3, 2021 – Jun 6, 2024 · Past); Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Denali Therapeutics Inc. (Director · Dec 7, 2017 – Jun 1, 2023 · Past); Editas Medicine, Inc. (Director · Feb 2, 2016 – Aug 17, 2017 · Past); Agios Pharmaceuticals, Inc. (Director · Jul 23, 2013 – Aug 10, 2016 · Past); Receptos Inc (Director · May 8, 2013 – Jul 17, 2013 · Past); Tetraphase Pharmaceuticals Inc (Director · Mar 19, 2013 – Mar 25, 2013 · Past); AVEO Pharmaceuticals Inc (Director · Mar 11, 2010 – May 12, 2011 · Past) | Director · Dec 6, 2017 – Jan 2, 2019 · Past |
| Martin Madaus Other companies: Haemonetics Corporation (Director · Since at least Jul 24, 2026); Hologic Inc (Director · Since at least Dec 6, 2024); Azenta, Inc. (interim President and CEO · Since at least Jan 30, 2024); Repligen Corporation (Chair of the Board · Since at least Feb 6, 2023); Standard BioTools Inc. (Director · Apr 4, 2022 – Oct 20, 2023 · Past); Covidien plc (Director · Dec 1, 2011 – Feb 20, 2014 · Past); Mettler-Toledo International, Inc. (Director · Jul 23, 2009 – Nov 18, 2014 · Past); Millipore Corp (CEO and President, Director · Feb 16, 2006 – Jul 14, 2010 · Past) | Director · Dec 6, 2017 – Jan 2, 2025 · Past |
| Keith Crandell Other companies: Kardigan, Inc. (Director · Since at least Jun 22, 2026); Metsera, Inc. (Director · Since at least Nov 13, 2025); 908 Devices Inc. (Director · Since at least Dec 17, 2020); Twist Bioscience Corporation (Co-Founder and Managing Director · Since at least Oct 30, 2018); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 28, 2023 · Past); Adesto Technologies Corporation (Director · Oct 26, 2015 – Jun 4, 2019 · Past); Celebrate Express Inc (Director · Oct 19, 2006 – Aug 29, 2008 · Past) | Director · Dec 6, 2017 – Apr 3, 2023 · Past |
| Marijn E Dekkers Other companies: Ginkgo Bioworks Holdings, Inc. (Director · Sep 16, 2021 – Jun 12, 2024 · Past); Quantum-Si Incorporated (Director · Jun 10, 2021 – May 11, 2022 · Past); Cerevel Therapeutics Holdings Inc (Director · Oct 27, 2020 – Aug 1, 2024 · Past); GE Aerospace (Director · Jun 12, 2012 – Apr 2, 2018 · Past); Biogen Inc. (Director · May 31, 2007 – Jun 3, 2009 · Past); Thermo Fisher Scientific Inc (Chief Executive Officer, Director · Jan 7, 2006 – Aug 17, 2009 · Past) | Director · Dec 6, 2017 – Jan 11, 2021 · Past |
| Everett Cunningham Other companies: GeneDx Holdings Corp. (Chief Executive Officer and a member of the Board · Since Nov 18, 2026); Illumina, Inc. (SVP, Chief Commercial Officer · Since at least Jun 10, 2024); Arvinas, Inc. (Director · Since at least Dec 15, 2022); EXACT Sciences Corporation (Chief Commercial Officer · Nov 1, 2021 – Apr 30, 2024 · Past); Quest Diagnostics Incorporated (SVP, Commercial · Feb 19, 2018 – Mar 1, 2019 · Past) | President and CEO, Director · Since at least Jan 8, 2026 |
| Karen A. Flynn Other companies: Stevanato Group S.p.A. (Director · Since at least Mar 18, 2026); Sotera Health Company (Director · Since at least Nov 13, 2023); Catalent Inc (Director · Jan 8, 2020 – Oct 27, 2023 · Past); Recro Pharma Inc (Director · Sep 3, 2015 – Dec 5, 2019 · Past); West Pharmaceutical Services, Inc. (Sr VP & Chief Commercial Offic · Jul 1, 2012 – Feb 19, 2019 · Past) | Director · Since at least Jun 6, 2022 |
| Kevin Hrusovsky Other companies: 908 Devices Inc. (Director · Since at least Dec 17, 2020); Da32 Life Science Tech Acquisition Corp (Director · Jul 27, 2021 – Jul 27, 2021 · Past); Revvity, Inc. (See Remarks · Feb 1, 2012 – May 31, 2013 · Past); SeraCare Life Sciences Inc (Director · May 10, 2011 – Apr 20, 2012 · Past); Caliper Life Sciences Inc (President & CEO, Director · Mar 3, 2009 – Nov 7, 2011 · Past) | Executive Chairman, Director · Dec 6, 2017 – Jul 5, 2022 · Past |
| Sarah E Hlavinka Other companies: ODP Corp (EVP-Chief Legal Officer & Secy · Since at least Jul 9, 2022); Telesis Bio, Inc. (Director · Jul 16, 2024 – Jul 24, 2024 · Past); Itron, Inc. (SVP, Gen. Counsel & Corp. Sec. · Aug 6, 2018 – Feb 24, 2022 · Past); Xerox Holdings Corporation (EVP, Gen. Counsel & Corp. Sec. · Jan 18, 2017 – Apr 6, 2018 · Past); ABM Industries Incorporated (EVP/GEN. COUNSEL/CORP. SECTY. · May 16, 2008 – Jan 14, 2017 · Past) | Director · Since at least Jul 25, 2019 |
| Brian J. Blaser Other companies: QuidelOrtho Corporation (President and Chief Executive Officer · Since at least May 6, 2024); Talis Biomedical Corp (President and CEO, Director · Dec 1, 2021 – Dec 1, 2021 · Past); Rockley Photonics Holdings Ltd (Director · Aug 11, 2021 – May 17, 2022 · Past); Abbott Laboratories (Executive Vice President · May 17, 2010 – May 23, 2019 · Past) | Director · Jan 6, 2023 – Jan 2, 2024 · Past |
All 50 people
| Person | Seat |
|---|---|
| Goldman Myla Lai Other companies: Akoya Biosciences Inc (Director · Since at least Sep 16, 2021); West Pharmaceutical Services, Inc. (Director · Since at least Feb 18, 2014); Sequenom Inc (Director · Sep 11, 2012 – Sep 7, 2016 · Past); Labcorp Holdings Inc. (EVP & Chief Medical Officer · Jan 5, 2006 – Nov 20, 2008 · Past) | Director · Since at least Jul 8, 2025 |
| Ivana Magovčević-Liebisch Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Feb 8, 2024); Vigil Neuroscience Inc (President and CEO, Director · Since at least Jan 6, 2022); Absci Corporation (Director · Jul 21, 2021 – Jun 8, 2022 · Past); Spyre Therapeutics, Inc. (Director · Jun 8, 2021 – Jun 22, 2023 · Past) | Director · Since at least Oct 2, 2024 |
| Jeffrey Elliott Other companies: ICON plc (Director · Since at least Jun 1, 2026); Sera Prognostics, Inc. (Director · Since at least Mar 20, 2025); Exagen Inc. (Director · Sep 18, 2019 – Jun 18, 2020 · Past); EXACT Sciences Corporation (Chief Financial Officer · Nov 8, 2016 – Apr 30, 2024 · Past) | COO of Exact Sciences · Since at least Aug 19, 2024 |
| Scott Mendel Other companies: Quantum-Si Incorporated (Director · Since at least May 11, 2023); Akoya Biosciences Inc (Director · Since at least Jun 11, 2021); GenMark Diagnostics Inc (President & CEO, Director · May 13, 2014 – Apr 22, 2021 · Past); Active Network Inc (Chief Financial Officer · May 24, 2011 – Nov 15, 2013 · Past) | Director · Since at least Jul 8, 2025 |
| David R Walt Other companies: Exicure, Inc. (Director · Sep 26, 2017 – Jun 4, 2020 · Past); Dare Bioscience, Inc. (Director · Feb 23, 2015 – Jan 3, 2017 · Past); Illumina, Inc. (Director · Apr 2, 2007 – Apr 7, 2016 · Past) | Director · Since at least Dec 6, 2017 |
| William P. Donnelly Other companies: T. Rowe Price Group, Inc. (Director · Since at least Nov 1, 2023); Ingersoll Rand Inc. (Lead Independent Director · Since at least May 11, 2017); Mettler-Toledo International, Inc. (Executive Vice President · Apr 19, 2006 – Dec 31, 2018 · Past) | Director · Since at least Aug 17, 2023 |
| Daniel Char Other companies: ImmunoGen Inc (SVP & CHIEF LEGAL OFFICER · Nov 21, 2022 – Feb 12, 2024 · Past); Evelo Biosciences, Inc. (General Counsel · Oct 29, 2018 – Jul 19, 2022 · Past) | Chief Legal Officer · Since at least Feb 23, 2026 |
| John M Connolly Other companies: Princeton Review Inc (Chief Executive Officer · Mar 8, 2011 – Apr 8, 2012 · Past); Edgar Online Inc (Director · Jan 28, 2010 – Aug 14, 2012 · Past) | Director · Dec 6, 2017 – Jan 2, 2020 · Past |
| Joseph Driscoll Other companies: Akoya Biosciences Inc (Chief Financial Officer · Apr 20, 2021 – Dec 22, 2022 · Past); PC Connection, Inc. (Sr. VP, CFO and Treasurer · Sep 1, 2015 – Sep 1, 2016 · Past) | Chief Financial Officer · Dec 6, 2017 – Jan 15, 2019 · Past |
| Laurie J Olson Other companies: Karuna Therapeutics Inc (Director · Aug 12, 2020 – Mar 18, 2024 · Past); Pfizer, Inc. (Executive Vice President · Jul 17, 2012 – Aug 13, 2018 · Past) | Director · Apr 27, 2021 – May 14, 2024 · Past |
| Malcolm Garret Hampton Other companies: IDEAYA Biosciences, Inc. (Director · Since at least Jun 26, 2020); Illumina, Inc. (SVP Clinical Genomics Group · Jan 26, 2017 – Jan 9, 2020 · Past) | Director · Since at least Nov 20, 2025 |
| Amee Desjourdy Other companies: Fortive Corporation (SVP - Chief People Officer · Since at least Jan 26, 2026) | Chief Human Resource Officer · Aug 19, 2019 – Aug 19, 2019 · Past |
| Amol Chaubal Other companies: Waters Corporation (SVP & Chief Financial Officer · Since at least May 12, 2021) | Chief Financial Officer · Apr 12, 2019 – May 3, 2021 · Past |
| Garret Hampton Other companies: IDEAYA Biosciences, Inc. (Director · Since at least Nov 4, 2026) | Since at least Nov 20, 2025 |
| John J Fry Other companies: Analogic Corporation (See Remarks · Nov 26, 2007 – Jun 22, 2018 · Past) | General Counsel & Secretary · Jun 14, 2019 – Aug 1, 2022 · Past |
| Michael A Doyle Other companies: Forrester Research, Inc. (Chief Financial Officer · Nov 3, 2020 – Dec 14, 2020 · Past) | CFO and Treasurer · Jul 12, 2021 – Sep 30, 2023 · Past |
| Vandana Sriram Other companies: Azenta, Inc. (SVP Finance & Corp. Controller · Feb 1, 2022 – Jan 31, 2023 · Past) | Chief Financial Officer · Since at least Aug 21, 2023 |
| William Geist Other companies: Bio-Techne Corp (PRESIDENT, PROTEIN SCIENCES · Since at least Jan 3, 2022) | Chief Operating Officer · Nov 16, 2020 – Feb 8, 2021 · Past |
| Alan Sachs | Director · Since at least Nov 20, 2025 |
| Amy Achorn | Investor Relations · Nov 12, 2024 – Nov 18, 2026 · Past |
| Anthony Catalano | Chief Operating Officer · Since at least Nov 19, 2026 |
| Benjamin Meadows | Chief Commercial Officer · Since at least Feb 23, 2026 |
| Bruce J Bal | VP of Ops, Service and Quality · Dec 6, 2017 – May 10, 2018 · Past |
| David C Duffy | SVP R&D and CTO · Dec 6, 2017 – Mar 23, 2022 · Past |
| Dawn Mattoon | Sr. VP, Diagnostics · Feb 23, 2018 – Apr 1, 2022 · Past |
| Erica Bell | Chief People Officer · Since at least Nov 19, 2026 |
| Ernest Orticerio | SVP Finance and Corporate Dev · Dec 6, 2017 – Jan 9, 2019 · Past |
| Geoff Albrecht | Senior Vice President and General Manager of Diagnostics · Since Jun 4, 2026 · Appointed, no departure found |
| Geoff Albrecht | SVP, General Manager, Diagnostics · Since at least Jun 4, 2026 |
| James Edward Gute Jr | Chief Commercial Officer · Since at least Aug 17, 2026 |
| Jason Faessler | Chief Financial Officer · Since at least Jun 9, 2026 |
| Jim Gute | Serve in the additional role of Interim President and CEO · Since Nov 18, 2026 · Appointed, no departure found |
| Jim Gute | Chief Commercial Officer and Interim President and CEO · Since at least Aug 10, 2026 |
| Joshua Young | Investor Relations · Since at least Apr 15, 2026 |
| Mark T Roskey | SVP, Strategic Partnerships · Dec 6, 2017 – Apr 1, 2022 · Past |
| Masoud Toloue | President & CEO, Director · Since at least Jun 9, 2021 |
| Michael Miller | Chief Technology and Product Officer · Since at least Feb 23, 2026 |
| Naren Bhat | Chief Strategy Officer · Since at least Nov 19, 2026 |
| Shawn Stetson | Interim CFO and Treasurer · May 11, 2021 – May 11, 2021 · Past |
| Yuri Fesko | Chief Medical Officer · Since at least Sep 14, 2026 |
Log in to ask 6ix AI your own questions about Quanterix Corporation.